Cardiac amyloidosis is an underdiagnosed cause of heart failure characterized by extracellular deposition of misfolded proteins. Advances in non-invasive imaging, including echocardiography, cardiac magnetic resonance imaging (CMR), and radionuclide imaging, have significantly enhanced the diagnostic accuracy and monitoring of cardiac amyloidosis. This review explores the role of each modality, their individual strengths, and current consensus recommendations. Emphasis is placed on the integration of multimodal imaging to guide diagnosis, prognosis, and therapeutic decisions in both AL and ATTR amyloidosis.
Keywords: amyloid light chains (AL) amyloidosis; cardiac MRI; cardiac amyloidosis; echocardiography; multimodality imaging; nuclear imaging; transthyretin (ATTR) amyloidosis.